Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IST:SELEC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.47 Med: 5.55 Max: 29.95
Current: 27.64
During the past 13 years, the highest EV-to-EBITDA of Selcuk Ecza Deposu Ticaret venayi AS was 29.95. The lowest was 2.47. And the median was 5.55.
IST:SELEC's EV-to-EBITDA is ranked worse than 93.88% of 98
companies
in the Medical Distribution industry
Industry Median: 8.65
vs IST:SELEC: 27.64
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Selcuk Ecza Deposu Ticaret venayi AS's PE Ratio (TTM) for today is calculated as:
Selcuk Ecza Deposu Ticaret venayi AS's share price for today is ₺241.50.
Selcuk Ecza Deposu Ticaret venayi AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺1.902.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selcuk Ecza Deposu Ticaret venayi AS EV-to-EBITDA Chart
IST:SELEC vs MCK, COR, CAH: EV-to-EBITDA Comparison
For the Medical Distribution subindustry, Selcuk Ecza Deposu Ticaret venayi AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selcuk Ecza Deposu Ticaret venayi AS EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Selcuk Ecza Deposu Ticaret venayi AS's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Selcuk Ecza Deposu Ticaret venayi AS's EV-to-EBITDA falls into.
Selcuk Ecza Deposu Ticaret venayi AS's current Enterprise Value is ₺144,715 Mil.
Selcuk Ecza Deposu Ticaret venayi AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺5,237 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) has a EV-to-EBITDA of 27.63 as of Jul. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Selcuk Ecza Deposu Ticaret venayi AS. This is 398% above median its historical median of 5.55. Over the past decade, Selcuk Ecza Deposu Ticaret venayi AS's EV-to-EBITDA has ranged from 2.47 to 29.95. According to the industry distribution chart, Selcuk Ecza Deposu Ticaret venayi AS ranks #92 out of 98 companies in the Medical Distribution industry, placing it in the top 93.9%.
Is Selcuk Ecza Deposu Ticaret venayi AS's EV-to-EBITDA too high?
Selcuk Ecza Deposu Ticaret venayi AS's current EV-to-EBITDA of 27.63 is 398% above median its 10-year median of 5.55. Over the past 10 years, this metric has ranged from a low of 2.47 to a high of 29.95. The Medical Distribution industry median EV-to-EBITDA is 8.65. Selcuk Ecza Deposu Ticaret venayi AS's value of 27.63 is 219.4% above this industry median. Based on the distribution chart, Selcuk Ecza Deposu Ticaret venayi AS ranks #92 out of 98 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Selcuk Ecza Deposu Ticaret venayi AS has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Selcuk Ecza Deposu Ticaret venayi AS's EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Selcuk Ecza Deposu Ticaret venayi AS ranks #92 out of 98 companies for EV-to-EBITDA. This places Selcuk Ecza Deposu Ticaret venayi AS in the lower half of its industry. The industry median EV-to-EBITDA is 8.65. Selcuk Ecza Deposu Ticaret venayi AS's value of 27.63 is 219.4% above this benchmark. Historically, Selcuk Ecza Deposu Ticaret venayi AS's own EV-to-EBITDA has ranged from 2.47 to 29.95 over the past decade. While the company's 10-year median is 5.55 vs. the industry median of 8.65, Selcuk Ecza Deposu Ticaret venayi AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.65, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Selcuk Ecza Deposu Ticaret venayi AS's current EV-to-EBITDA of 27.63 is 219.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Selcuk Ecza Deposu Ticaret venayi AS. For the Medical Distribution industry, the median EV-to-EBITDA is 8.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Selcuk Ecza Deposu Ticaret venayi AS's current EV-to-EBITDA is 27.63, which is 398% above median its own 10-year median of 5.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selcuk Ecza Deposu Ticaret venayi AS stock overvalued right now?
Based on GuruFocus' analysis, Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) is currently considered Significantly Overvalued. The stock's GF Value™ is ₺89.93, compared to a current price of ₺241.50 — trading 168.5% above its estimated fair value. The current EV-to-EBITDA is 27.63, which is 398% above median its 10-year median of 5.55 and 219.4% above the Medical Distribution industry median of 8.65. Selcuk Ecza Deposu Ticaret venayi AS's overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC), the current EV-to-EBITDA is 27.63 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) Overvalued in 2026?
Based on GuruFocus' analysis, Selcuk Ecza Deposu Ticaret venayi AS stock appears to be overvalued.
The current stock price of ₺241.50 is trading 168.5% above its estimated GF Value™ of ₺89.93.
GuruFocus considers Selcuk Ecza Deposu Ticaret venayi AS to be Significantly Overvalued.
Key valuation signals for IST:SELEC:
EV-to-EBITDA: 27.63 (398% above median its 10-year median of 5.55)
GF Value™: ₺89.93 vs. price of ₺241.50 (168.5% above fair value)
Industry Position: 219.4% above the Medical Distribution median (#92 of 98)
No single metric tells the full story. See the IST:SELEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selcuk Ecza Deposu Ticaret venayi AS Business Description
Selcuk Ecza Deposu Ticaret ve Sanayi AS and its subsidiaries are in the business of export and import of drugs and patent medicines, medical supplies with pharmacy depot operations and also organize distribution channels between drug manufacturers, hospitals, and pharmacies. The company also distributes cosmetics, personal care, infant food, vitamins, medical and similar products.
80GF Score
Get the complete analysis for IST:SELEC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:SELEC has been successfully added to your 
